Halozyme Therapeutics Dividend
Dividend criteria checks 0/6
Halozyme Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | US$2.22 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Dec 09Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today
Sep 08Halozyme Therapeutics raises $625M through convertible senior notes due 2028
Aug 16Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off
Aug 03Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jul 26Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Jun 10Halozyme: Antares Pharma Bolsters Growth Prospects
May 19Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Apr 25Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if HALO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HALO's dividend payments have been increasing.
Dividend Yield vs Market
Halozyme Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (HALO) | n/a |
Market Bottom 25% (US) | 1.6% |
Market Top 25% (US) | 4.9% |
Industry Average (Biotechs) | 2.9% |
Analyst forecast in 3 Years (HALO) | n/a |
Notable Dividend: Unable to evaluate HALO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HALO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate HALO's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HALO has not reported any payouts.